The diagnostic value of iron oxide nanoparticles for imaging of myocardial inflammation – quo vadis?

Table 1 Representative examples for iron oxide-containing contrast agents

Coating	Examples	Size in nm	Comment
Carboxymethyl- dextran	Ferumoxytol (Feraheme™)	17-31	FDA approved for anaemia and in clinical use
Carboxydextran	Ferucarbotran (SHU 555A, Resovist®)	45-60	FDA approved. Discontinued from clinical use in 2009.
Dextran	Ferumoxtran (USPIO, AMI-227, NC100150, BMS-180549)	17-21	Discontinued after 37 clinical studies phase I-III in 2010.
Dextran	Ferumoxides (Feridex™)	100	Discontinued from clinical use in 2008.
Crosslinked dextrans	CLIO-Cy5.5	30-35	Experimental use
Citrate	VSOP-C184	4-7	Experimental use, clinical phase I study in 2004

Representative examples for iron oxide-containing contrast agents for CMR with clinical, commercial and/or considerable experimental use adopted and modified from Weissleder et al. [34]. Additional information and further iron oxide-based contrast agents can be seen elsewhere [40]. CLIO: cross-linked dextran iron oxide nanoparticles

ISSN: 1532-429X